A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer\
- Assess the overall survival of patients with resectable ductal pancreatic
adenocarcinoma undergoing extended versus standard pancreatoduodenectomy.
OUTLINE: Patients are randomized to undergo standard pancreatoduodenectomy (PD) or PD with
extended lymph node resection after an exploratory laparotomy.
Patients receive adjuvant chemoradiation therapy 4-6 weeks after surgery, if no metastases
are evident. Radiation therapy is given every week for 5 weeks. Fluorouracil/leucovorin
calcium is administered by rapid IV push daily within 2 hours of radiation on days 1-4 of
week 1 and days 29-31 of week 5.
Patients are followed every 4 months for the first year, then every 6 months for the next 2
PROJECTED ACCRUAL: 50 patients will be accrued per group for a total of 100 patients.
Allocation: Randomized, Primary Purpose: Treatment
Randall K. Pearson, MD
United States: Federal Government
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|